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Abstract: (1) We investigated the involvement of serum magnesium level in early alcoholic liver
disease (ALD), gut barrier dysfunction, and inflammation in alcohol use disorder (AUD) patients;
and lastly, the efficacy of 2-week abstinence and medical management to alleviate hypomagnesemia.
(2) Forty-eight heavy drinking AUD patients (34 males (M)/14 females (F)) participated in this study.
Patients were grouped by serum alanine aminotransferase (ALT) level (a marker of liver injury) as
group 1 (Group 1 (Gr.1); ALT ≤ 40 U/L, 7M/8F, without any indication of early-stage ALD) and
group 2 (Group 2 (Gr.2); ALT > 40 U/L, 27M/6F or early-stage ALD). These patients were sub-divided
within each group into patients with normal magnesium (0.85 and more mmol/L) and deficient
magnesium (less than 0.85 mmol/L) levels. All participants were assessed at baseline (BL) and
received standard medical management for 2 weeks with reassessment at the treatment end (2w).
(3) Female participants of this study showed a significantly lower baseline level of magnesium than
their male counterparts. Gr.2 patients showed a greater propensity in the necrotic type of liver cell
death, who reported higher chronic and recent heavy drinking. Magnesium level improved to the normal range in Gr.2 post-treatment, especially in the hypomagnesemia sub-group (0.77 ± 0.06 mmol/L
(BL) vs. 0.85 ± 0.05 mmol/L (2w), p = 0.02). In Gr.2, both apoptotic (K18M30) and necrotic (K18M65)
responses were significantly and independently associated with inflammasome activity comprising of LBP (Lipopolysaccharide binding-protein) and TNFα (Tumor necrosis factor -α), along with
serum magnesium. (4) In AUD patients with liver injury, 2-week medical management seems to
improve magnesium to a normal level. This group exhibited inflammatory activity (LBP and TNFα)
contributing to clinically significant hypomagnesemia. In this group, the level of magnesium, along
with the unique inflammatory activity, seems to significantly predict apoptotic and necrotic types of
hepatocyte death.
Keywords: alcoholic liver disease; alcohol use disorder; early-stage ALD; heavy drinking; hypomagnesemia
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1. Introduction
Alcohol-associated liver disease (ALD) is a spectrum of liver diseases, including
steatosis, hepatitis, and fibrosis/cirrhosis, caused secondary to chronic excessive alcohol
intake [1]. Several clinical studies investigate patients diagnosed with the advanced form
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of ALD; albeit those with early ALD are often missed [2,3]. This has led to a significant
gap in our knowledge about the pathophysiology of early ALD. The detection of specific
biomarkers that could characterize early ALD would help to serve as diagnostic tools
for the better management of these patients, and offer an assessment of the treatment
course [4].
Alcohol intake leads to various electrolyte disturbances, including deficiencies in magnesium [5]. Hypomagnesemia has been observed with both acute as well as chronic alcohol
abuse [6–9]. Research has shown that chronic alcohol use alters magnesium homeostasis
and its transport in liver cells [6]. One study has even shown that increasing hypomagnesemia is found on muscle biopsy with the increasing severity of liver injury [10]. Another
recent study showed that heavy and chronic alcohol drinking is involved in hypomagnesemia that could be contributory to liver injury in early-stage ALD [11].
There is a lack of data on electrolyte imbalances in early-stage alcohol-associated
liver disease. This is a field of continued clinical interest, as evidenced by recent papers
that showed that mortality is lower in patients with liver disease who took high doses of
magnesium [12]. There is ongoing research to explore the role of electrolyte imbalances as
biomarkers for ALD, and the pathophysiology of these disturbances [13]. Alcohol could
dysregulate the immunological status that eventually adversely impacts upon liver health
and brain activity [14]. Importantly, we do not know if the pattern of alcohol drinking is
involved in the type and extent of liver cell death. The liver cell death markers K18M65 and
K18M30 represent the necrotic and apoptotic types of liver cell death [3,15]. The shift in the
type of liver cell death may show early changes along with the liver injury and/or heavy
drinking patterns, though such characterization has not been investigated yet. Additionally,
these alterations may have variability in the degree and severity by the modifying effects
of age and sex of the individuals involved in heavy and chronic drinking [16].
In this study, we aim to characterize the level of heavy drinking markers by the extent
of the liver cell death marker, K18M65, in alcohol use disorder (AUD) patients. We further
investigate the role of serum magnesium in context of heavy drinking pattens consequential
in liver injury/liver cell death, cytokine and pro-inflammatory responses, and candidate
pathological pathways involved in liver injury at baseline and post-2-week standard of
care (SOC, 2w) assessment. Lastly, we explored the role of modifiers of ALD, such as age
and sex variables/factors.
2. Results
2.1. Demographics, Drinking, and Nutritional Status
Twenty-five out of 48 AUD patients reported hypomagnesemia at admission. There
was no difference in age and BMI between the two groups (grouped by the level of ALT
as the primary factor). In total, 17 out of 33 (51%) AUD patients with mild liver injury
at admission (Gr.2) exhibited hypomagnesemia, whereas 8 out of 15 (53%) AUD patients
without liver injury at admission (Group 1 or Gr.1) were found to have hypomagnesemia.
Out of the 15 Gr.1 patients, the number of female patients who exhibited hypomagnesemia
exceeded their male counterparts by three-fold (Table 1). In Group 2 (Gr.2), there were
notably more males than females (4.5 times more), and males who exhibited hypomagnesemia outnumbered their female counterparts by more than three-fold. Lifetime drinking
(by the number of years) was significantly higher in Gr.2 compared to Gr.1. HDD90 and
NDD90 heavy drinking markers were numerically higher in Gr.2 as well.
Table 1. Baseline assessment of demographics, drinking history, liver injury, magnesium and nutritional level, blood cell measures, cytokine and gut-permeability markers, and liver cell death markers.
Group 1 (Normal Initial ALT, Gr.1)
Measures

Group 2 (Elevated Initial ALT, Gr.2)

Normal Mg
(n = 7; 46.67%)

Low Mg (n = 8; 53.33%)

Total
(n = 15; 31.25%)

Age (years)

37.64 ± 10.5

42.9 ± 12.4

BMI (kg/m2 )

31.31 ± 8.2

25.9 ± 7.4

Between Group
p-Value

Normal Mg
(n = 16; 48.48%)

Low Mg
(n = 17; 51.52%)

Total
(n = 33; 68.75%)

40.45 ± 11.4

41.4 ± 9.5

47.3 ± 9.5

44.45 ± 9.8

NS

28.45 ± 8.0

25.9 ± 4.7

26.1 ± 2.9

25.99 ± 3.7

NS
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Table 1. Cont.
Group 1 (Normal Initial ALT, Gr.1)
Measures

Sex (F/M)

Normal Mg
(n = 7; 46.67%)
2/5

Group 2 (Elevated Initial ALT, Gr.2)

Between Group
p-Value

Low Mg (n = 8; 53.33%)

Total
(n = 15; 31.25%)

Normal Mg
(n = 16; 48.48%)

Low Mg
(n = 17; 51.52%)

Total
(n = 33; 68.75%)

6/2

8/7

2/14

4/13

6/27

NA

NS

Baseline Drinking History
1511.2 ± 653.3

809.2 ± 598.0

1160.21 ± 703.33

1111.2 ± 593.0

1048.65 ± 440.7

1078.98 ± 512.80

HDD90 c

75.4 ± 14.0

54.57 ± 21.9

65.00 ± 20.71

68.94 ± 22.2

76.24 ± 21.9

72.69 ± 21.18

NS

AvgDPD90

19.36 ± 6.54

14.19 ± 7.6

16.78 ± 7.33

15.46 ± 6.5

13.18 ± 4.5

14.29 ± 5.60

NS

NDD90 c

TD90

76.86 ± 56.86

56.86 ± 23.25

66.86 ± 21.48

72.00 ± 20.71

78.49 ± 15.85

75.49 ± 18.40

NS

LTDH c

12.5 ± 6.7

9.63 ± 5.3

10.86 ± 5.86

17.3 ± 10.1

17.8 ± 10.4

17.56 ± 10.06

0.025

ALT (IU/L) c,d

27.86 ± 7.0

25.25 ± 10.5

26.47 ± 8.86

87.19 ± 48.13

109.24 ± 62.8

98.55 ± 56.43

NA

AST (IU/L) c,d

31.14 ± 9.8

37.50 ± 26.5

34.53 ± 20.09

115.56 ± 95.5

144.94 ± 105.8

130.70 ± 100.45

<0.01

AST: ALT

1.16 ± 0.4

1.43 ± 0.6

1.30 ± 0.51

1.23 ± 0.6

1.35 ± 0.8

1.29 ± 0.70

NS

0.77 ± 0.06

0.85 ± 0.10

NS

1.18 ± 1.1

0.97 ± 1.05

NS

6.03 ± 2.19

0.061

Baseline Liver Injury Markers

Baseline Magnesium Levels
Serum Mg mmol/L a,b

0.9 ± 0.09

0.76 ± 0.04

0.83 ± 0.10

0.93 ± 0.07

Baseline Nutritional Status
CONUT

1.00 ± 1.0

1.00 ± 1.7

1.00 ± 1.36

0.75 ± 0.9

Baseline Blood Cell Types
WBC (K/uL) c

7.03 ± 3.2

7.93 ± 3.05

AMC
(K/uL)

0.62 ± 0.26

ANC (K/uL)

4.29 ± 2.4

IL-1β (pg/mL) a

7.51 ± 3.03

6.42 ± 2.3

5.65 ± 2.1

0.46 ± 0.21

0.53 ± 0.24

0.58 ± 0.28

0.46 ± 0.16

0.52 ± 0.23

NS

4.66 ± 2.5

4.49 ± 2.37

3.64 ± 1.7

3.49 ± 1.7

3.56 ± 1.68

NS

0.66 ± 0.50

0.57 ± 0.60

0.62 ± 0.53

0.50 ± 0.29

0.45 ± 0.23

0.47 ± 0.26

NS

IL-6 (pg/mL) a,c,d

2.25 ± 1.15

3.68 ± 4.41

2.97 ± 3.18

3.64 ± 2.16

3.98 ± 3.94

3.82 ± 3.19

NS

TNF-α (pg/mL)

1.74 ± 0.77

1.17 ± 0.52

1.45 ± 0.70

1.93 ± 0.59

2.26 ± 1.15

2.11 ± 0.93

0.025

Baseline Candidate Cytokine Response

IL-8 (pg/mL) a

13.25 ± 26.19

4.63 ± 5.23

8.94 ± 18.68

4.05 ± 2.09

9.00 ± 13.92

6.69 ± 10.42

NS

MCP-1 (pg/mL) a

96.03 ± 29.75

110.87 ± 67.01

103.45 ± 50.41

115.91 ± 56.43

115.66 ± 72.96

115.78 ± 64.66

NS

LPS (EU/mL)

0.078 ± 0.06

0.080 ± 0.05

0.08 0.05

0.106 ± 0.06

0.110 ± 0.06

0.11 ± 0.06

NS

LBP (ng/mL)

624.51 ± 742.92

2009.87 ± 3374.97

1317.19 ± 2455.31

2497.59 ± 3096.29

1759.19 ± 2750.63

2092.66 ± 2886.01

NS

+sCD14 (×10
pg/mL)

8865.95 ± 2238.92

8962.71 ± 1509.51

8917.56 ± 1813.29

9193.12 ± 1997.19

9744.99 ± 1614.74

9477.42 ± 1803.29

NS

K18M65 (IU/L)

138.62 ± 63.85

456.42 ± 528.24

308.11 ± 410.12

856.21 ± 1083.77

922.37 ± 827.66

890.29 ± 945.63

0.027

K18M30 (IU/L)

514.08 ± 854.73

278.89 ± 165.09

388.65 ± 584.36

361.13 ± 415.01

378.20 ± 342.46

378.20 ± 342.46

NS

0.682 ± 0.59

1.333 ± 0.78

1.03 ± 0.76

2.325 ± 1.50

2.214 ± 1.26

2.27 ± 1.36

0.002

Baseline Candidate Gut-dysfunction Markers

Baseline Liver Cell Death Markers

M65:M30

BMI: Body mass index, TD90: Total drinks past 90 days, HDD90: heavy drinking days past 90 days,
AvgDPD90: Average drinks per drinking day past 90 days, NDD90: number of drinking days past 90 days,
NNDD90: number of non-drinking days past 90 days, LTDH: lifetime drinking history (in years),
ALT: serum alanine aminotransferase, AST: serum aspartate aminotransferase, AST:ALT—ratio of AST by ALT,
CONUT: Controlling Nutritional Status Test (unit: numerical), WBC: white blood cells count, AMC: absolute
monocyte count, ANC: absolute neutrophil count, Il1β: interleukin 1 beta, IL-6: interleukin 6, TNFα: tumor-like
necrotic factor alpha, LPS: lipopolysaccharide, LBP: LPS binding protein, sCD14: soluble cell of differentiation type 14, K18M65: soluble CK18, K18M30: caspase-cleaved fragment of CK18, M65:M30—ratio of K18M65
by K18M30. a Statistically significant difference between the hypomagnesemia sub-groups of the two groups.
b Statistically significant difference between the sub-groups exhibiting normal magnesium levels of the two
groups. c Statistically significant difference between the sub-groups of Gr.1. d Statistically significant difference
between the sub-groups of Gr.2.

2.2. Baseline Magnesium Level and Nutritional Status
The serum magnesium level was deficient in 8/15 patients of Gr.1, and 17/33 patients
of the Gr.2 (Table 1). Notably, both the groups did not show any statistical or numerical
difference in the CONUT scores, thus excluding the dietary deficiency could be justified.
Gr.2 patients with hypomagnesemia had elevated CONUT scores compared to the Gr.2
patients with a normal magnesium level (Table 1). However, the hypomagnesemia exhibited
in the patients of both the groups had similarly deficient levels of magnesium (Figure 1a).
When we reviewed the SM between the sexes in the whole subject pool, we found that
the females had a greater adverse response to heavy drinking, which corresponded to a
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reference range for serum magnesium is 0.85–1.10 mmol/L. Data presented as Mean ± Standard DeDeviation. Statistical significance was set at p < 0.05. *** p < 0.001. **** p < 0.0001.
viation. Statistical significance was set at p < 0.05. *** p < 0.001. **** p < 0.0001.
2.3. Baseline Gut-Dysfunction and Pro-Inflammatory Response
LPS, LBP, and +sCD14 were numerically higher in Gr.2 compared to Gr.1 values. TNFα was a distinct pro-inflammatory cytokine that showed significant elevation only in Gr.2.
In Gr.2, IL-6 and MCP-1 were numerically high, and IL-8 and IL-1β were lower, suggesting
immunological uniqueness by the staging of the liver disease (Table 1).
2.4. Baseline Liver Injury, and Liver Cell Death
As anticipated, liver injury characterized by ALT (as well as AST) was significantly
higher in Gr.2 by approximately four-fold, and both were clinically and numerically significant compared to the Gr.1 values (Table 1). Liver injury progression as recorded by the
AST:ALT ratio was comparable in both the groups by their individual numerical value
and was not statistically different. Both the necrotic marker, K18M65 and the necrosis
trend, K18M65:M30 were markedly and significantly elevated in the Gr.2. Importantly, Gr.2
patients who exhibited hypomagnesemia had approximately double the level of necrosis
and necrotic trend compared to the Gr.1 patients exhibiting hypomagnesemia.
The markers of heavy alcohol drinking in the statistical paradigm grouped by normal
or high levels of K18M65 showed significant elevations in candidate recent heavy and
chronic drinking markers. HDD90 and NDD90 as the acute and chronic markers of heavy
drinking, respectively, and LTDH, were all significantly high in patients who also had
reported clinically significant K18M65 levels (Figure 2a–c). Such differences were not
evident with the differences in the K18M30 levels.
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2.6. Post-SOC Evaluation
Normal magnesium level was attained in Gr.2 with two weeks of medical management,
importantly in the hypomagnesemia sub-group. In Gr.1, this change was not observed in
the patients with baseline hypomagnesemia. Performing repeated analyses of variance for
the baseline to the 2w K18M65:M30 ratio, K18M65, and K18M30 (markers of cell death)
among the hypomagnesemia sub-groups only for both the groups, we found that the
drop in the Gr.2 patients with hypomagnesemia was larger and exhibited a statistically
significant main effect for the K18M65:M30 (p = 0.022) and K18M30 ratio (p = 0.051). To
confirm the true positivity of this result, we performed Receiver Operating Characteristic
(ROC) curve analysis for the restoration of magnesium level at post-treatment stage in Gr.2.
The area under the curve (AUROC) was 0.857 (a very good fit for true positivity) at high
significance, p = 0.014, compared to their corresponding baseline values (Figure 5). Notably,
the 2w TNF-α was correspondingly elevated, along with K18M65 in the Gr.2 patients, a
potential explanation of the continuity of the necrotic process and with K18M65 remaining
at a sub-clinical high level at 2w, especially in the hypomagnesemia sub-group (Table 2).
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Table 2. Post-study assessment of liver injury, magnesium level, blood measures, cytokine, and
gut-permeability markers and liver cell death markers.
Group 1 (Normal Initial ALT, Gr.1)

Measures

Group 2 (Elevated Initial ALT, Gr.2)

Normal Mg

Low Mg

Total

Normal Mg

ALT (IU/L)

58.33 ± 34.7

50.67 ± 36.7

54.50 ± 32.24

AST (IU/L)

78.0 ± 79.98

68.67 ± 58.53

73.33 ± 62.89

AST: ALT

1.16 ± 0.56

1.27 ± 0.18

1.22 ± 0.38

0.54 ± 0.13

Between Group
p-Value

Low Mg

Total

68.75 ± 18.4

56.00 ± 22.3

61.67 ± 20.50

NS

36.00 ± 6.98

30.40 ± 7.09

32.89 ± 7.22

0.073

0.61 ± 0.28

0.58 ± 0.22

0.001

0.85 ± 0.05

0.88 ± 0.07

NS

NS

Post-Study Liver Injury Markers

Post-Study Magnesium Levels
Serum Mg mmol/L

0.90 ± 0.06

0.80 ± 0.13

0.85 ± 0.10

0.92 ± 0.07

Post-Study Candidate Cytokine Response
IL-1β (pg/mL)

0.64 ± 0.39

0.62 ± 0.93

0.63 ± 0.68

0.38 ± 0.25

0.78 ± 0.96

0.59 ± 0.74

IL-6 (pg/mL)

2.44 ± 1.02

3.44 ± 3.56

2.94 ± 2.57

3.30 ± 2.29

2.95 ± 0.95

3.11 ± 1.69

NS

TNF-α (pg/mL) a

2.03 ± 0.68

1.49 ± 0.64

1.76 ± 0.69

2.45 ± 0.85

2.61 ± 0.78

2.53 ± 0.85

0.004

2.36 ± 0.47

4.35 ± 6.02

3.36 ± 4.23

2.69 ± 1.27

3.68 ± 2.57

3.21 ± 2.09

NS

120.63 ± 36.19

94.98 ± 51.76

107.81 ± 44.92

120.97 ± 44.50

124.60 ± 57.67

122.91 ± 51.10

NS

LPS (EU/mL)

0.07 ± 0.047

0.08 ± 0.057

0.07 ± 0.05

0.07 ± 0.02

0.06 ± 0.03

0.06 ± 0.03

NS

LBP (ng/mL)

2201.25 ± 2823.20

1630.45 ± 2287.74

1896.82 ± 2473.80

2484.89 ± 3406.92

1917.26 ± 2334.62

2191.92 0 ± 2867.93

NS

+sCD14 (×10 pg/mL)

6318.33 ± 1845.33

7393.96 ± 1103.19

6892.00 ± 1541.57

6851.46 ± 1855.94

7739.69 ± 1778.08

7295.57 ± 1843.93

NS

K18M65 (IU/L) b

239.57 ± 106.56

373.50 ± 483.61

311.00 ± 355.79

357.25 ± 129.83

726.00 ± 1678.11

541.62 ± 1185.69

NS

K18M30 (IU/L)

508.47 ± 794.91

247.45 ± 154.50

369.26 ± 548.55

239.59 ± 76.14

246.68 ± 148.57

243.02 ± 114.95

NS

1.16 ± 0.80

1.08 ± 0.72

1.56 ± 0.52

1.35 ± 0.56

1.46 ± 0.54

NS

IL-8 (pg/mL)
MCP-1 (pg/mL)

Post-Study Candidate Gut-dysfunction Markers

Post-Study Liver Cell Death Markers

M65:M30 b

0.98 ± 0.66

ALT: serum alanine aminotransferase, AST: serum aspartate aminotransferase, AST:ALT—ratio of AST by ALT,
CONUT: Controlling Nutritional Status Test (unit: numerical), WBC: white blood cells count, AMC: absolute
monocyte count, ANC: absolute neutrophil count, Il1β: interleukin 1 beta, IL-6: interleukin 6, TNFα: tumorlike necrotic factor alpha, LPS: lipopolysaccharide, LBP: LPS binding protein, sCD14: soluble cell of differentiation type 14, K18M65: soluble CK18, K18M30: caspase-cleaved fragment of CK18, M65:M30—ratio of
K18M65 by K18M30. a Statistically significant difference between the hypomagnesemia sub-groups of the two
groups. b Statistically significant difference between the sub-groups exhibiting normal magnesium levels of the
two groups.
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3. Discussion
More than half of the AUD patients admitted in the study, regardless of the study
randomization, exhibited hypomagnesemia. Most of the study patients exhibited hypomagnesemia; those who exhibited hypomagnesemia with liver injury also reported clinically
and statistically significant elevation in the AST levels. Thus, all AUD patients regardless of
liver injury could potentially have low magnesium, though the progression of liver injury
could have a higher probability in patients with AUD and hypomagnesemia. Hypomagnesemia can be caused by one of three pathophysiologic mechanisms, including reduced
intestinal absorption, increased urinary losses, or intracellular shift [17]. It is interesting
to note that heavy and chronic alcohol drinking could cause hypomagnesemia via all
three mechanisms. Both heavy drinking episodes and their frequency could contribute to
the progressive deficiency of magnesium. Notably, females were found to have a greater
adverse response to heavy drinking that corresponded to the lower magnesium level
than their male counterparts, suggesting sexual dimorphism in the context of pathological
consequence in the magnesium level from heavy and chronic drinking. In this study, the
difference in the heavy drinking markers with the necrotic cell death of the hepatocytes
was established, which was a novel finding. We found that the hypomagnesemia was
evident in the AUD patients with normal liver enzymes, who also showed exacerbated gut
dysfunction uniquely characterized by more than 3-fold higher values of LBP. The ratio of
K18M65 by K18M30 is an indication of necrotic shift, and we found that this shift positively
corresponded to the recent heavy alcohol drinking that attained statistical significance in
the context of the magnesium level. This is an interesting finding, since this ratio has been
also observed in AUD patients with early-stage ALD, as well as in alcoholic hepatitis (AH)
patients, in which it indicates the necrotic shift that corresponds with the severity of liver
status [18,19].
Contributing factors leading to hypomagnesemia include a poor nutritional status
leading to decreased absorption [6,20,21], increased urinary losses [20,22], and impaired
magnesium homeostasis [9]. Overt hypomagnesemia leads to weakness, ataxia, cramps,
tetany, seizures, and arrhythmias/electrocardiographic changes [23]. Newer research has
been looking at different stages/level of magnesium deficiency and has found that even
subclinical magnesium deficiency may be one of the leading causes of chronic diseases
and early mortality [24]. Clinical implications of hypomagnesemia in liver disease are
significant and may lead to supplementation being one of the recommended modalities in
the medical management of alcohol-associated liver disease.
Studies in alcohol-fed rats have shown that magnesium supplementation helped with
oxidative stress and tissue damage, as evidenced by elevated total antioxidant status (TAS)
in serum, the activity of glutathione peroxidase, and the ratio of reduced glutathione to oxidized glutathione (GSH/GSSG) in the liver, as well as tissue histopathological changes [25].
Magnesium supplementation in rats with liver damage has been shown to have anti-fibrotic
properties, with improvement in oxidant and antioxidant parameters and histopathological
examination [26].
The 2w SOC assessment yielded some interesting findings. Two weeks of SOC sufficiently treated the deficiency in the magnesium levels of AUD patients who exhibited
baseline liver injury; this corresponded well with the lowering of the AST and AST:ALT
levels in these AUD patients [27]. ALT level was higher in Gr.2 after 2 weeks of the treatment; this could be attributed to the persisting inflammation that could not be alleviated
by the end of the study. This could indicate that the active inflammation may take more
time to alleviate than the ongoing cell death and ALD progression. One trial of magnesium
supplementation study on human chronic alcohol users in Finland showed that when
given magnesium supplementation, patients have a lowering of serum AST level and may
have a decreased risk of death from alcoholic liver disease [28]. Due to its role in cellular
regeneration and anti-oxidation, hypomagnesemia in the early stages of liver disease may
be one of the factors leading to the progression of this liver disease. ALT also remained
borderline high at 2w SOC assessment; however, it was corrected significantly from the
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baseline values. This drop could be validated by the response change in the necrosis marker,
K18M65, which correspondingly dropped to the borderline high level. Furthermore, the
K18M30 values normalized completely at 2w in the same cohort. Studies in non-alcoholic
fatty liver disease support the protective role of magnesium as a disease control [29].
All of these patients were inpatient, and they maintained abstinence, and active alcohol
drinking was not a contributing factor. Thus, patients receiving SOC with nutritional therapy and the management of any of the clinical presentation of AUD, including withdrawal,
were apt for recovery [30] in this patient cohort with mild liver injury exhibiting hypomagnesemia. None of these patients had alcohol-associated cirrhosis or hepatitis. However,
one study showed that compared to patients with non-alcoholic steatosis, patients with
steatohepatitis had a lowered serum magnesium level [31].
This study had several limitations due to the extent and scope of the study design.
This study was a proof-of-concept study, and the sample size was relatively small. This
limited the ability of the paradigm to evaluate the vulnerability in females and males
independently. Females were less in number in each group by the sub-group categories;
thus, running statistics was not feasible at the sub-group level (specially within sub-group
male to female comparisons). A smaller sample size also poses a greater challenge for
research compliance, since the post-treatment has lesser subjects (compared to the baseline
strength) who provided the research samples. This clinical study was designed as a crosssectional longitudinal treatment by time investigation. However, the study aims were
secondary under a larger protocol; thus, studying all the corresponding biomarkers were
not within the scope at the present time when we completed the investigation. The study
was aimed at 2 weeks of treatment, given that the anticipated mild liver injury should be
treated within the timeframe effectively. It was a revelation that many patients will progress
regardless of their ALT or AST levels. Thus, it is important to look for the mechanisms
that could predict the underlying course of liver health and pathology. We did not test
magnesium levels in AUD patients with cirrhosis (AC) and hepatitis (AH); thus, we do
not know what unique differences in the response change could have progressed along
with the advancement of the ALD. We have started a new protocol to study magnesium
response in AH patients. Studies show that advanced ALD and the level of magnesium
could be a clinical direction of investigation [32]. A necrosis and apoptotic assessment
could reveal the pathological status better; however, such assays are not readily available as
point of care. The magnesium level could show a corresponding change in the underlying
necrotic and apoptotic cascade, which is a readily available point of care (POC) and could
be helpful in suggesting the medical management of the AUD patients who could be at
high risk of developing and progressing into an advanced form of ALD.
Further hypothesis-driven well-structured treatment trials and large longitudinal
studies are warranted to explore the potential of magnesium as an adjunct therapy of liver
disease. Our findings supported the role of serum magnesium as a potential biomarker for
alcohol-associated early-stage liver injury and liver cell death. Our study also describes
the corresponding changes in the magnesium level, along with liver cell death and its
alleviation with the treatment course over time.
4. Materials and Methods
This investigation is a secondary aim of a larger clinical investigation (NCT#00106106)
that was conducted at the National Institute on Alcohol Abuse and Alcoholism (NIAAA)
at the National Institutes of Health (NIH), Bethesda, MD. A total of 48 male and female
AUD patients within an age range of 21–65 yrs participated in this study, receiving a detox
program for one month at the NIH Clinical Center. All study patients were diagnosed
with AUD based on DSM-IV, TR edition [33]. The alcohol dependence module of the
Structured Clinical Interview I, and alcohol withdrawal were administered for reaching the
AUD diagnosis. All study patients received medical management and addiction therapy
throughout their stay; more details are available in our previous publications [34,35].
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Further detailed information on admission, exclusion, and inclusion could be reviewed in
a primary publication on investigational drug efficacy [36].
A few important exclusion criteria are described here: (i) the presence of severe psychiatric and/or somatic illnesses, including advanced lung disease, unstable cardiovascular
disease (decompensation, as demonstrated through chest X-ray and pathological electrocardiogram), and/or renal failure (creatinine clearance < 30 mL/min). Other exclusion criteria
were (ii) the presence of HIV, (iii) pregnancy or ongoing breastfeeding, and (4) pronounced
anxiety provoked by enclosed spaces, and/or positive urine screen for any illicit drug.
No AUD patient exhibited any clinical evidence of advanced ALD or gout disease. All
patients received standard clinical inpatient care for alcohol detoxification and medical
management according to the “Human Subjects Protection” guidelines of NIH.
4.1. Demographics, Drinking, and Laboratory Evaluations
Blood was drawn once patients consented to participate in the inpatient study. On
admission, blood samples were collected for a serum chemistry panel (Table 1) that included
tests for liver injury and the serum magnesium (SM) level. Demographic information (age,
sex, and body mass index (BMI)) and drinking history were also collected for the study.
Heavy drinking measures were collected from the Timeline Follow-back questionnaire [37].
Markers of heavy drinking derived from the TLFB reported in the past 90 days were
“Total Drinks” (TD90), “Number of Drinking Days” (NDD90), “Number of Non-Drinking
Days” (NNDD90), “Average Drinking per Drinking Days” (AvgDPD90), and “Heavy
Drinking Days” (HDD90). Chronic drinking was reported using lifetime drinking history
(LTDH) [38]. We used the “Controlling Nutritional Status Test” (CONUT) information on
these patients to assess their nutritional status [39]. The alanine aminotransaminase (ALT)
level was used as a biomarker for early liver injury (Medline Plus-National Institutes of
Health, 2014). Normal serum alanine aminotransferase (ALT) values were set at ≤40 IU/L,
and patients were categorized as Group 1: those with normal ALT level; and Group 2:
those with ALT > 40 IU/L, as indicative of mild liver injury. The reference normal range for
serum magnesium is 0.85–1.10 mmol/L. Patients with serum magnesium <0.85 mmol/L
were considered as having magnesium deficiency. All laboratory assays were performed
by the Department of Laboratory Medicine at NIH Bethesda MD, per its guidelines (https:
//medlineplus.gov/ency/article/003487.htm 9 January /2022).
4.2. Laboratory Assays
Frozen plasma samples at −80 degree Celsius were thawed and assayed. Plasma
cytokeratin 18 whole protein (K18M65) and caspase-cleaved fragment (K18M30) were
analyzed using enzyme-linked immunosorbent assay (ELISA) (Peviva-VLVbio, Nacka,
Sweden) according to the manufacturer’s instructions. Clinically significant K18 is as follows: K18M65 > 500 U/L or K18M30 > 250 U/L (was used for categorical differences in the
Figure 2 analyses). Plasma pro-inflammatory cytokines, TNF-α, interleukin 1β, interleukin
6, and interleukin 8 (IL-1β, IL-6, and IL-8), PAI-1, and monocyte chemoattractant protein-1
(MCP-1) were obtained via multianalyte chemiluminescent detection using Mulliplex kits
(Millipore, Billerica, MA) on the Luminex (Luminex, Austin, TX, USA) platform according
to manufacturers’ instructions. Plasma lipopolysaccharide (LPS) and lipopolysaccharide
(LBP) levels were assayed using the Kinetic Chromogenic Limulus Amebocyte Lysate Assay
(Lonza, Walkersville, MD) according to the manufacturer’s instructions.
4.3. Statistical Analysis
One-way ANOVA was used to evaluate demographic and drinking history measures.
Univariate analysis of covariance (ANCOVA) was used to evaluate differences in the serum
magnesium level in both the groups and by the modifiers of ALD, primarily by sex, within
each of the liver injury groups as factors. Drinking history and other demographic factors
were tested as confounders (covariates) of the extent and progression of liver injury. Linear
regression analysis was used to characterize the association of liver injury markers and
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SM independently (or with covariables in the context of drinking history measures, sex,
cytokines, and gut permeability factors). Repeated analyses of variance were performed to
evaluate the treatment effects of the detox program and intervention on restoring normal
SM by group over time (at 2w). To eliminate the possibility of a type I error, Receiver
Operating Characteristic (ROC) analysis and area under the ROC (AUROC) were used
to estimate the probability of the outcome of treatment in Gr.2 patients with documented
hypomagnesemia, compared to those without, at the end of the study. SPSS 27.0 (IBM
Chicago, IL, USA) and Microsoft 365 Excel (MS Corp, Redmond WA) were used for
statistical analysis and data computation. Statistical significance was established at p < 0.05.
Data are expressed as M ± SD (Mean ± standard deviation), unless otherwise noted.
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